Overview:

Summary

“Hit by the Infamous Patent Cliff, Big Pharma Strategize Counter Measures for the Future” provides key update on the much awaited “patent cliff”, the term coined for the cumulative patent expirations from 2009-15 of blockbuster pharmaceutical drugs, and its effects on the pharmaceutical industry. The patent cliff peaks in 2011 with the patent expiry of Zyprexa and Lipitor, among others. The report takes a look at the Big Pharma’s strategies to counter the impact of huge revenue losses implicated by the patent cliff in the coming years. It also highlights the strategies of three top pharmaceutical companies who stand to lose the maximum these tough times.

Scope

- Patent Cliff - Overview, Key patent expirations, companies involved
- Counter Measure Strategies- Move to generics/biosimilars, M&A activities, R&D cutbacks
- Company outlook – Pfizer, Eli Lilly and Sanofi-Aventis
- Future of Pharma R&D

Reasons to buy

- Evaluate the short-term implications of the first major patent cliff in the new millennium.
- Understand the strategic measures employed by the Big Pharma to counter its effect
- Assess the aggressive M&A landscape in the current pharmaceutical industry
- Examine the latest trends in the pharmaceutical and bio-pharmaceutical industry – R&D outsourcing, focus on biosimilars, emergence of the branded generics

1 Table of Contents 1
2 Summary 1
3 Patent Cliff – End of the blockbuster Era? 1
3.1 Restructuring the Business Model 2
3.1.1 Move to Generics, and Biosimilars! 2
3.1.2 Mergers, Acquisitions and Collaboration Agreements 2
3.1.3 R&D budget cuts and increased outsourcing 2
3.2 Preparing for the Future 3
3.2.1 Pfizer 3
3.2.2 Eli Lilly 3
3.2.3 Sanofi-Aventis 3
3.3 Future of Pharma R&D – Innovators to Distributors, More Biotech 4
4 Appendix 4
4.1 Methodology 4
4.1.1 Coverage 4
4.1.2 Secondary Research 4
4.1.3 Primary Research 5
4.1.4 Expert Panel Validation 5
4.2 Contact Us 5
4.3 Disclaimer 5